Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investors Overview

Aravive is a clinical stage biotechnology company focused on developing innovative therapies that target important survival pathways for cancer. Aravive’s lead candidate, AVB-S6-500, is a novel, high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. AXL receptor signaling plays an important role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. Aravive is poised to initiate the Phase 1b portion of its first Phase 1b/2 clinical trial of AVB-S6-500 combined with standard of care therapies in patients with platinum resistant ovarian cancer before the end of 2018, and intends to expand development into additional tumor types.

Latest Corporate Presentation